Home LiteratureArticle Details
PMID: 24150415 Published · ppublish English Journal Article Review

Delivery materials for siRNA therapeutics.

Nature materials ·Vol. 12 ·No. 11 ·2013-11-00 ·Pages 967-77

Kanasty R, Dorkin JR, Vegas A, Anderson D

Abstract

RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene. To achieve the clinical potential of RNAi, delivery materials are required to transport short interfering RNA (siRNA) to the site of action in the cells of target tissues. This Review provides an introduction to the biological challenges that siRNA delivery materials aim to overcome, as well as a discussion of the way that the most effective and clinically advanced classes of siRNA delivery systems, including lipid nanoparticles and siRNA conjugates, are designed to surmount these challenges. The systems that we discuss are diverse in their approaches to the delivery problem, and provide valuable insight to guide the design of future siRNA delivery materials.

MeSH Terms
Animals Drug Carriers/chemistry Humans Nanoparticles/chemistry RNA, Small Interfering/chemistry,genetics,therapeutic use
Chemicals
Drug Carriers RNA, Small Interfering
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Kanasty Rosemary
1] Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA [2] David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
Dorkin Joseph Robert
Vegas Arturo
Anderson Daniel
References (107)
107 references, click to expand
  1. Inhibition of protein kinase C by cationic amphiphiles.
    Biochemistry. 1992 Sep 22;31(37):9025-30 PMID: 1390689
  2. Attacking the genome: emerging siRNA nanocarriers from concept to clinic.
    Curr Opin Pharmacol. 2012 Aug;12(4):427-33 PMID: 22726555
  3. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.
    Nucleic Acids Res. 2006 Jan 12;34(1):322-33 PMID: 16410612
  4. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
    Pharm Res. 2013 Feb;30(2):342-51 PMID: 22983644
  5. Effects of cholesterol on the lamellar and the inverted hexagonal phases of dielaidoylphosphatidylethanolamine.
    Biochim Biophys Acta. 1996 Mar 15;1289(2):209-16 PMID: 8600975
  6. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    J Control Release. 2012 Nov 10;163(3):267-76 PMID: 23000694
  7. Silencing or stimulation? siRNA delivery and the immune system.
    Annu Rev Chem Biomol Eng. 2011;2:77-96 PMID: 22432611
  8. In vivo activity of nuclease-resistant siRNAs.
    RNA. 2004 May;10(5):766-71 PMID: 15100431
  9. In vivo disassembly of IV administered siRNA matrix nanoparticles at the renal filtration barrier.
    Biomaterials. 2013 Mar;34(9):2350-8 PMID: 23261216
  10. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.
    Mol Ther. 2010 Jul;18(7):1357-64 PMID: 20461061
  11. Tunable pH-sensitive liposomes composed of mixtures of cationic and anionic lipids.
    Biophys J. 2000 Sep;79(3):1438-46 PMID: 10969005
  12. Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells.
    Pediatr Surg Int. 2010 Dec;26(12):1185-91 PMID: 20737153
  13. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers.
    Curr Med Chem. 2004 Jan;11(2):179-97 PMID: 14754416
  14. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Eur J Pharm Biopharm. 2008 Nov;70(3):718-25 PMID: 18647651
  15. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface.
    Nat Nanotechnol. 2013 Feb;8(2):137-43 PMID: 23334168
  16. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles.
    Eur J Cell Biol. 2004 Apr;83(3):97-111 PMID: 15202568
  17. Sheddable coatings for long-circulating nanoparticles.
    Pharm Res. 2008 Jan;25(1):55-71 PMID: 17551809
  18. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.
    Nat Biotechnol. 2008 Apr;26(4):431-42 PMID: 18376398
  19. Galactose and N-acetylgalactosamine-specific endocytosis of glycopeptides by isolated rat hepatocytes.
    Cell. 1980 Nov;22(2 Pt 2):611-20 PMID: 7448875
  20. Rapid chiral assembly of rigid DNA building blocks for molecular nanofabrication.
    Science. 2005 Dec 9;310(5754):1661-5 PMID: 16339440
  21. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.
    Nat Biotechnol. 2009 Sep;27(9):839-49 PMID: 19701187
  22. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms.
    Circ Res. 2007 Feb 2;100(2):158-73 PMID: 17272818
  23. Elimination pathways of systemically delivered siRNA.
    Mol Ther. 2011 Feb;19(2):381-5 PMID: 21119623
  24. Current progress of siRNA/shRNA therapeutics in clinical trials.
    Biotechnol J. 2011 Sep;6(9):1130-46 PMID: 21744502
  25. Structural effects of carbohydrate-containing polycations on gene delivery. 3. Cyclodextrin type and functionalization.
    Bioconjug Chem. 2003 May-Jun;14(3):672-8 PMID: 12757394
  26. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection.
    Biochemistry. 1996 May 7;35(18):5616-23 PMID: 8639519
  27. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
    Mol Pharm. 2009 May-Jun;6(3):659-68 PMID: 19267452
  28. Factors affecting the clearance and biodistribution of polymeric nanoparticles.
    Mol Pharm. 2008 Jul-Aug;5(4):505-15 PMID: 18672949
  29. New class of polymers for the delivery of macromolecular therapeutics.
    Bioconjug Chem. 1999 Nov-Dec;10(6):1068-74 PMID: 10563777
  30. Lipid-based vectors for siRNA delivery.
    J Drug Target. 2012 Nov;20(9):724-35 PMID: 22994300
  31. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.
    Nat Rev Drug Discov. 2010 Jan;9(1):57-67 PMID: 20043028
  32. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes.
    Gut. 2013 Sep;62(9):1328-39 PMID: 23172890
  33. siRNA conjugate delivery systems.
    Bioconjug Chem. 2009 Jan;20(1):5-14 PMID: 19053311
  34. Nonbilayer phase of lipoplex-membrane mixture determines endosomal escape of genetic cargo and transfection efficiency.
    Mol Ther. 2005 May;11(5):801-10 PMID: 15851018
  35. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.
    Sci Transl Med. 2011 Jan 19;3(66):66ra6 PMID: 21248316
  36. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.
    Nat Biotechnol. 2008 May;26(5):561-9 PMID: 18438401
  37. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles.
    Bioconjug Chem. 2007 Mar-Apr;18(2):456-68 PMID: 17326672
  38. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery.
    Science. 1998 Jul 3;281(5373):78-81 PMID: 9651248
  39. Challenges in the pharmaceutical development of lipid-based short interfering ribonucleic acid therapeutics.
    Expert Opin Drug Deliv. 2012 Feb;9(2):171-82 PMID: 22251440
  40. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
    Toxicol Appl Pharmacol. 2009 Apr 1;236(1):97-108 PMID: 19371615
  41. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids.
    Gene Ther. 2001 Aug;8(15):1188-96 PMID: 11509950
  42. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.
    Nature. 2004 Nov 11;432(7014):173-8 PMID: 15538359
  43. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
    Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21 PMID: 17379663
  44. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
    Angew Chem Int Ed Engl. 2012 Aug 20;51(34):8529-33 PMID: 22782619
  45. Knocking down barriers: advances in siRNA delivery.
    Nat Rev Drug Discov. 2009 Feb;8(2):129-38 PMID: 19180106
  46. Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.
    Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):E797-803 PMID: 22421433
  47. In vivo tumor imaging using a novel RNAi-based detection mechanism.
    Nanomedicine. 2012 May;8(4):393-8 PMID: 22349098
  48. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.
    Nat Biotechnol. 2005 Aug;23(8):1002-7 PMID: 16041363
  49. Membrane activity and transfection ability of amphipathic polycations as a function of alkyl group size.
    Bioconjug Chem. 2005 Sep-Oct;16(5):1204-8 PMID: 16173799
  50. Polymers in small-interfering RNA delivery.
    Nucleic Acid Ther. 2011 Jun;21(3):133-47 PMID: 21749290
  51. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
    Sci Transl Med. 2012 Apr 18;4(130):130ra48 PMID: 22517885
  52. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation.
    J Am Chem Soc. 2012 Apr 25;134(16):6948-51 PMID: 22475086
  53. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma.
    Cancer Res. 2005 Oct 1;65(19):8984-92 PMID: 16204072
  54. Targeted delivery systems for oligonucleotide therapeutics.
    AAPS J. 2009 Mar;11(1):195-203 PMID: 19296227
  55. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery.
    Bioconjug Chem. 2003 Nov-Dec;14(6):1122-32 PMID: 14624625
  56. Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.
    Mol Ther Nucleic Acids. 2012 Aug 14;1:e37 PMID: 23344179
  57. RNAi-mediated gene silencing in non-human primates.
    Nature. 2006 May 4;441(7089):111-4 PMID: 16565705
  58. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.
    Mol Ther. 2008 Apr;16(4):734-40 PMID: 18362929
  59. Effects of structure of beta-cyclodextrin-containing polymers on gene delivery.
    Bioconjug Chem. 2001 Mar-Apr;12(2):280-90 PMID: 11312690
  60. Triggered release of doxorubicin following mixing of cationic and anionic liposomes.
    Biochim Biophys Acta. 2002 Sep 20;1565(1):129-35 PMID: 12225861
  61. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles.
    Biotechnol Bioeng. 2008 Mar 1;99(4):975-85 PMID: 17929316
  62. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo.
    J Biol Chem. 2001 Oct 5;276(40):37577-84 PMID: 11479285
  63. Endosomolysis by masking of a membrane-active agent (EMMA) for cytoplasmic release of macromolecules.
    Bioconjug Chem. 2003 Jan-Feb;14(1):51-7 PMID: 12526692
  64. Lipid-like materials for low-dose, in vivo gene silencing.
    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9 PMID: 20080679
  65. Rational design of cationic lipids for siRNA delivery.
    Nat Biotechnol. 2010 Feb;28(2):172-6 PMID: 20081866
  66. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography.
    J Clin Invest. 2004 Nov;114(10):1475-83 PMID: 15545998
  67. Action and reaction: the biological response to siRNA and its delivery vehicles.
    Mol Ther. 2012 Mar;20(3):513-24 PMID: 22252451
  68. Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor.
    J Med Chem. 1995 Apr 28;38(9):1538-46 PMID: 7739012
  69. Lateral organization of liquid-crystalline cholesterol-dimyristoylphosphatidylcholine bilayers. Evidence for domains with hexagonal and centered rectangular cholesterol superlattices.
    Biochemistry. 1995 Sep 12;34(36):11568-81 PMID: 7547888
  70. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer.
    Biochim Biophys Acta. 2011 Dec;1816(2):232-46 PMID: 21840374
  71. Nanoparticle delivery of cancer drugs.
    Annu Rev Med. 2012;63:185-98 PMID: 21888516
  72. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery.
    Nat Nanotechnol. 2012 Jun 03;7(6):389-93 PMID: 22659608
  73. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system.
    J Pharm Sci. 1995 Apr;84(4):493-8 PMID: 7629743
  74. Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery.
    Biomacromolecules. 2012 Mar 12;13(3):664-75 PMID: 22288825
  75. RNA interference.
    Nature. 2002 Jul 11;418(6894):244-51 PMID: 12110901
  76. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics.
    Nat Nanotechnol. 2011 Sep 11;6(10):658-67 PMID: 21909084
  77. Nanovector delivery of siRNA for cancer therapy.
    Cancer Gene Ther. 2012 Jun;19(6):367-73 PMID: 22555511
  78. In vivo delivery of RNAi with lipid-based nanoparticles.
    Annu Rev Biomed Eng. 2011 Aug 15;13:507-30 PMID: 21639780
  79. Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications.
    Adv Drug Deliv Rev. 2012 Aug;64(11):1046-59 PMID: 22329941
  80. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Nature. 2010 Apr 15;464(7291):1067-70 PMID: 20305636
  81. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.
    Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3137-42 PMID: 22315430
  82. pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo.
    Bioconjug Chem. 2013 Mar 20;24(3):314-32 PMID: 23305315
  83. Strategies in the design of nanoparticles for therapeutic applications.
    Nat Rev Drug Discov. 2010 Aug;9(8):615-27 PMID: 20616808
  84. Cyclodextrin-modified polyethylenimine polymers for gene delivery.
    Bioconjug Chem. 2004 Jul-Aug;15(4):831-40 PMID: 15264871
  85. Structural effects of carbohydrate-containing polycations on gene delivery. 1. Carbohydrate size and its distance from charge centers.
    Bioconjug Chem. 2003 Jan-Feb;14(1):247-54 PMID: 12526715
  86. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy.
    Mol Pharm. 2012 Feb 6;9(2):299-309 PMID: 22171592
  87. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.
    Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):12982-7 PMID: 17652171
  88. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.
    Nat Biotechnol. 2007 Oct;25(10):1149-57 PMID: 17873866
  89. Combinatorial approach to determine functional group effects on lipidoid-mediated siRNA delivery.
    Bioconjug Chem. 2010 Aug 18;21(8):1448-54 PMID: 20715849
  90. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
    Bioconjug Chem. 2010 May 19;21(5):797-802 PMID: 20397686
  91. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.
    Nucleic Acid Ther. 2012 Dec;22(6):380-90 PMID: 23181701
  92. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer.
    Gene Ther. 2008 Sep;15(17):1193-9 PMID: 18401434
  93. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection.
    Mol Ther. 2013 May;21(5):973-85 PMID: 23439496
  94. Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions.
    Langmuir. 2011 Mar 1;27(5):1907-14 PMID: 21250743
  95. Asymmetry in the assembly of the RNAi enzyme complex.
    Cell. 2003 Oct 17;115(2):199-208 PMID: 14567917
  96. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging.
    Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54 PMID: 17875985
  97. A review of nanocarriers for the delivery of small interfering RNA.
    Biomaterials. 2012 Oct;33(29):7138-50 PMID: 22796160
  98. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
    Cancer Discov. 2013 Apr;3(4):406-17 PMID: 23358650
  99. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity.
    Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3974-9 PMID: 18305167
  100. Update on the glomerular filtration barrier.
    Curr Opin Nephrol Hypertens. 2009 May;18(3):226-32 PMID: 19374010
  101. Folate-targeted therapies for cancer.
    J Med Chem. 2010 Oct 14;53(19):6811-24 PMID: 20666486
  102. Atomic structure and chemistry of human serum albumin.
    Nature. 1992 Jul 16;358(6383):209-15 PMID: 1630489
  103. Design and synthesis of novel N-acetylgalactosamine-terminated glycolipids for targeting of lipoproteins to the hepatic asialoglycoprotein receptor.
    J Med Chem. 2004 Nov 4;47(23):5798-808 PMID: 15509179
  104. Nucleic acid nanostructures for biomedical applications.
    Nanomedicine (Lond). 2013 Jan;8(1):105-21 PMID: 23256495
  105. Imidazole groups on a linear, cyclodextrin-containing polycation produce enhanced gene delivery via multiple processes.
    J Control Release. 2006 Nov 28;116(2):179-91 PMID: 16891028
  106. Development of a nonviral gene delivery vehicle for systemic application.
    Bioconjug Chem. 2002 May-Jun;13(3):630-9 PMID: 12009955
  107. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues.
    Ann N Y Acad Sci. 2009 Sep;1175:32-9 PMID: 19796075
Article Info
Journal
Nature materials
Abbr.
Nat Mater
ISSN
1476-1122
DOI
10.1038/nmat3765
Published
2013-11-00
Pages
967-77
Language
English
Region
England
NLM ID
101155473
Subset
IM
External Links
PubMed source DOI: 10.1038/nmat3765 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2